Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment

Annals of Pharmacotherapy

Volumn 44, Issue 4, 2010, Pages 727-732

  Lowe, Erin J ^a   Ackman, Margaret L ^a  

^a ALBERTA HEALTH SERVICES   (Canada)

Author keywords

Adverse drug reaction; Clozapine; Olanzapine; Tobacco smoking cessation

Indexed keywords

CANNABIS; CIPROFLOXACIN; CLOZAPINE; CYTOCHROME P450; FLUOXETINE; LITHIUM SULFATE; NORCLOZAPINE; OLANZAPINE; VALPROIC ACID; ZIPRASIDONE;

AGITATION; AKATHISIA; AKINESIA; ARTICLE; AUDITORY HALLUCINATION; BIPOLAR DISORDER; BRADYKINESIA; BRADYPNEA; CANNABIS SMOKING; CIGARETTE SMOKING; CLINICAL EXAMINATION; COMPETITIVE INHIBITION; CONCENTRATION (PARAMETERS); CONFUSION; DAYTIME SOMNOLENCE; DELIRIUM; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG METABOLISM; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FATIGUE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERSALIVATION; IRRITABILITY; MONOTHERAPY; MUSCLE RIGIDITY; MYOCARDITIS; PARANOIA; PARANOID SCHIZOPHRENIA; PARKINSONISM; PHARMACIST; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SMOKING CESSATION; SOMNOLENCE; SYMPTOM; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; UROSEPSIS;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CLOZAPINE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; SCHIZOPHRENIA, PARANOID; SMOKING CESSATION;

EID: 77950617446     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M398     Document Type: Article

References (21)

1. The health consequences of smoking: a report of the surgeon general. [Atlanta, GA]: Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. Washington, DC: O2NLM: QV 137 H4347, 2004.
2. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005;76:135-157 (Pubitemid 40812332)
3. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness a population-based prevalence study. JAMA 2000;284:2606-2610
4. Zullino DF, Delessert D, Eap CB, Preisig M, Baumann P. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 2002;17:141-143 (Pubitemid 34442196)
5. Haslemo T, Eikeseth PH, Tanum L, Molden E, Refsum H. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol 2006;62:1049-1053 (Pubitemid 44786497)
6. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 2004;76:178-184 (Pubitemid 39013407)
7. Ming DS, Heathcote J. Therapeutic drug monitoring of clozapine and norclozapine in human serum using ultra-performance liquid chromatog- raphy tandem mass spectrometry. J Anal Toxicol 2009;33:198-203.
8. e-CPS. Ottawa, ON: Canadian Pharmacists Association. c2005. www. intranet2.capitalhealth.ca/pharmacy/ePublications1/index.asp (accessed 2009 Nov 27). (Files updated every 2 weeks.)
9. Rostami-Hodejegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 2004;24:70-78
10. Seppala NH, Leinonen EV, Lehtonen ML, Kivisto KT. Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharmacol Toxicol 1999;85:244-246
11. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993;13:383-390 (Pubitemid 24026099)
12. Meyer JM. Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol 2001;21:569-574
13. Carrillo JA, Herraiz AG, Ramos SI, Gervasini G, Vizcaino S, Benitez J. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psycho- pharmacol 2003;23:119-127 (Pubitemid 36368788)
14. Roth MD, Marques-Magallanes JA, Yuan M, Sun W, Tashkin DP, Hankinson O. Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta-9-tetrahydrocannabinol. Am J Respir Cell Mol Biol 2001;24:339-344 (Pubitemid 32228383)
15. Yamamoto I, Watanabe K, Matsunaga T, Kimura T, Funahashi T, Yoshimura H. Pharmacology and toxicology of major constituents of marijuana - on the metabolic activation of cannabinoids and its mechanism. J Toxicol 2003;22:577-589 (Pubitemid 37523698)
16. Bornheim LM, Lasker JM, Raucy JL. Human hepatic microsomal metabolism of delta1-tetrahydrocannabinol. Drug Metab Dispos 1992;20:241-246.
17. Jain S, Chawla JM, Theethira TG, Strassnig M, Chengappa KN. Changes in cigarette consumption in psychiatric patients: impact on side- effects or the efficacy of clozapine and olanzapine. Acta Neuropsych 2008;20:324-326
18. Brownlowe K, Sola C. Clozapine toxicity in smoking cessation and with ciprofloxacin. Psychosomatics 2008;49:176. (Pubitemid 351364993)
19. McCarthy RH. Seizures following smoking cessation in a clozapine responder. Pharmacopsychiatry 1994;27:210-211 (Pubitemid 24291953)
20. Skogh E, Bengtsson F, Nordin C. Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. Ther Drug Monit 1999;21:580-583 (Pubitemid 29468329)
21. Ayd FJ. Clozapine: a unique new neuroleptic. Int Drug Ther News 1974; 9:1-12.